Alopecia Areata Trial, Recruiting NCT06512753 Sponsor: Erasmus Medical Center Condition: Alopecia Areata
Back to Alopecia Areata

Alopecia Areata Trial, Recruiting

NCT06512753
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You have been diagnosed with a condition called lichen planopilaris (LPP), a type of scarring hair loss
  • You are willing to sign a consent form agreeing to take part in the study
  • You do not have any known allergies or medical reasons that would prevent you from taking either of the two study medications (hydroxychloroquine or methotrexate)

Who may not be able to join:

  • Your skin or scalp biopsy results show a different diagnosis than LPP
  • You are unable to follow the study requirements, such as taking medications as directed, attending clinic visits, or completing questionnaires
  • You have eye problems such as damage to the retina or macula (confirm with trial site)
  • You have a muscle weakness condition called myasthenia gravis
  • You weigh less than 35 kg (about 77 lbs)
  • You are currently trying to conceive a child (this applies to both men and women), are pregnant, or are breastfeeding
  • You have severe kidney or liver disease, liver scarring, or issues with alcohol use
  • You have problems with your bone marrow or a weakened immune system
  • You have low levels of red blood cells, white blood cells, or platelets
  • You have poor nutritional status, including low protein levels in your blood
  • You have a known allergy or sensitivity to the medication methotrexate
  • You have had lung damage caused by methotrexate in the past, or you have significantly reduced lung function

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: DirkJan Hijnen, MD, PhD, Erasmus Medical Center

Phone: (010) 704 01 10

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Erasmus Medical Center
Registry
ClinicalTrials.gov
Start date
1 July 2024
Est. completion
1 July 2026

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

LPPAI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov